Clinical trials: CAR-T
MRD-positive, Acute Lymphoblastic Leukemia
Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL
To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia.
- Trial name
- NCT03919526
- Testing
- anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Relapsed/Refractory CD19-positive B-ALL
Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
This study is an open-label, single-arm clinical trial designed to evaluate the safety and tolerability of QH103 cell infusion in subjects with CD19-positive R/R B-ALL.
- Trial name
- NCT07491263
- Testing
- Cyclophosphamide, Fludarabine, QH103 Cell Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Fujian Medical University
Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL)
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of OriV508 injection for patients with relapsed/refractory…
- Trial name
- NCT07101705
- Testing
- OriV508 Injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
B-cell Malignancies
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
The study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) and CD20 (4SCAR20), CD22 (4SCAR22), CD30 (4SCAR30), CD38 (4SCAR38), CD70…
- Trial name
- NCT03125577
- Testing
- 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell
Long-term Follow-up Study of Patients Receiving CAR-T Cells
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital.
- Conditions
- Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma
- Trial name
- NCT03375619
- Testing
- Long-Term Follow-Up of Participants who Received CAR-T cells
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Medical College of Wisconsin
High-grade Glioma, WHO Grade Ⅳ Glioma
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4…
- Trial name
- NCT06482905
- Testing
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Where
- 4 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Tcelltech Inc.
Refractory Systemic Lupus Erythematosus
IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)
The study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria.
- Trial name
- NCT06513429
- Testing
- IM19 CAR-T cells
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Peking University Third Hospital
Non-Hodgkin Lymphoma
'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL
This is a single-arm open-label phase I/II trial studying the safety and efficacy of focal 're-priming' radiation therapy (RT) to FDG-avid residual sites of disease in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) patients…
- Trial name
- NCT04601831
- Testing
- Focal radiation therapy (RT)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Gastric Cancer
Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial
The goal of this clinical trial is to assessing the safety and tolerability of XKDCT086 cells against recurrent or refractory solid tumors with Claudin18.2 positivity.This experiment proposes to enroll 9-18 patients, the…
- Trial name
- NCT05952375
- Testing
- Chimeric antigen receptor T cell preparation targeting Claudin18.2
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Non Hodgkin Lymphoma
Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford
This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.
- Trial name
- NCT05416554
- Testing
- Neuropsychological testing
- Where
- United States
- Sponsor
- Stanford University
Multiple Myeloma, Multiple Myeloma in Relapse
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or GPRC5D or both sequentially in the treatment of Relapsed/ Refractory…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma, Refractory
- Trial name
- BAH2573 (NCT07032129)
- Testing
- BCMA/GPRC5D CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Essen Biotech
Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
This study characterizes cardiac events following standard of care chimeric antigen receptor T cell therapy in patients with aggressive B-Cell Lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Conditions
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04870853
- Testing
- Electronic Health Record Review
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Lymphoid Hematological Malignancies
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy.
- Trial name
- NCT07472972
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Glioblastoma
CART-EGFRvIII + Pembrolizumab in GBM
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
- Trial name
- NCT03726515
- Testing
- CART-EGFRvIII T cells, Pembrolizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Hepatocellular Carcinoma
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infused autologous armored GPC3-directed CAR-T in patients with advanced hepatocellular carcinoma refractory to prior…
- Trial name
- NCT05926726
- Testing
- CAR-GPC3 T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- RenJi Hospital
T Cell Non-Hodgkin Lymphoma
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL.
- Trial name
- VIPER101 (NCT06420089)
- Testing
- Senza5 CART5
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vittoria Biotherapeutics
Acute Lymphoblastic Leukemia
2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell Therapy
The proposed research will compare the effects of TBI prior to CAR T cell infusion to the current standard of care using lymphodepletion.
- Trial name
- NCT07856758
- Testing
- CAR T cell therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphomas, B-cell Lymphomas
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
To find the highest tolerable dose of JV-213 (a type of autologous CAR T cell therapy) that can be given to patients who have B-cell lymphoma that is relapsed or refractory.
- Trial name
- NCT05773040
- Testing
- JV-213, Leukapheresis
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard…
- Trial name
- NCT05016778
- Testing
- GPRC5D-CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Non-hodgkin Lymphoma
Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
This is a multi-center, open-label, single-arm, phase I/II trial to evaluate the safety and efficacy of HY004 treatment in Adult patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma (r/r B-NHL).
- Trial name
- NCT06005649
- Testing
- HY004
- Sponsor
- Juventas Cell Therapy Ltd.